Axsome Therapeutics
AXSM
$255.17
+0.55%
Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders, operating within the high-risk, high-reward biotechnology industry. The company has established itself as a commercial-stage player with a focus on conditions with limited treatment options, leveraging its portfolio which includes the recently launched antidepressant Auvelity (AXS-05). The current investor narrative is dominated by the company's transition from a clinical-stage entity to a commercial one, with intense focus on the rapid revenue ramp of its lead products and the path to profitability, as evidenced by significant year-over-year sales growth and ongoing operational scaling.…
AXSM
Axsome Therapeutics
$255.17
Investment Opinion: Should I buy AXSM Today?
Rating & Thesis: Hold. The stock presents a compelling growth story with proven commercial traction, but its premium valuation and persistent cash burn create an asymmetric risk/reward profile at current levels, warranting caution despite the bullish analyst sentiment.
Supporting Evidence: The bullish case is supported by explosive 65% YoY revenue growth, industry-leading gross margins of 93.7%, and a narrowing net loss (improving from -$74.9M to -$28.6M YoY). However, the valuation is demanding at a trailing PS of 14.2x, and the company remains cash flow negative with a negative ROE of -207.5%. The forward PS of 2.4x implies the market expects revenue to more than double to $3.76B, leaving little margin for error. The stock's 114% one-year gain suggests much of the near-term optimism is already priced in.
Risks & Conditions: The two biggest risks are a deceleration in revenue growth below 50% and an inability to stem cash burn, which would pressure the high valuation and potentially necessitate dilutive financing. This Hold rating would upgrade to a Buy if the stock corrects to the $160-$170 support zone (offering a better entry point) or if the company demonstrates a clear path to positive operating cash flow in the next two quarters. Conversely, a downgrade to Sell would be triggered by quarterly revenue growth decelerating below 30% or a significant equity dilution event. The stock is currently overvalued relative to its near-term fundamentals but fairly valued if its long-term growth projections are met.
Sign up to view all
AXSM 12-Month Price Forecast
AXSM is a high-conviction, high-risk growth story in transition. The commercial launch is undeniably successful, with revenue soaring and losses narrowing. However, the stock's 114% run-up in the past year and premium valuation leave little room for error. The investment hinges entirely on the company's ability to maintain hyper-growth while navigating toward cash flow breakeven. The stance is neutral due to the balanced risk/reward at the current price; the upside is capped by valuation, while the downside is significant if execution stumbles. An upgrade to bullish would require evidence of sustained operating margin improvement and a clear reduction in quarterly cash burn. A downgrade to bearish would be triggered by any material slowdown in the revenue growth trajectory.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Axsome Therapeutics's 12-month outlook, with a consensus price target around $331.72 and implied upside of +30.0% versus the current price.
Average Target
$331.72
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$204 - $332
Analyst target range
Analyst coverage for AXSM appears limited, with only 8 analysts providing estimates according to the provided data, and no consensus price target or recommendation distribution is included. The available data shows institutional ratings from firms like Guggenheim, Wells Fargo, RBC Capital, UBS, and Jefferies, all maintaining 'Buy' or 'Overweight' equivalents as recently as March 2026, indicating sustained bullish sentiment among the covering firms. The lack of a published average target price and wide range in revenue estimates (low of $3.16B to high of $4.48B for the estimated period) points to significant uncertainty and variability in modeling the company's commercial trajectory. The implications of limited and fragmented analyst coverage are significant; AXSM, despite its ~$9.1 billion market cap, may still be considered a mid-cap biotech with higher volatility and less efficient price discovery. The unanimous bullish ratings from the firms that do cover it suggest strong conviction in the near-term commercial story, but the absence of a consolidated target and the wide revenue estimate range underscore the high-risk, high-reward nature of the investment, where forecasts are highly sensitive to prescription trends and market penetration assumptions.
Bulls vs Bears: AXSM Investment Factors
The evidence is currently balanced but leans bullish due to the undeniable strength of the revenue ramp and improving profitability trends, which are the primary drivers for a commercial-stage biotech. The bull case is anchored in the 65% YoY revenue growth and high gross margins, which validate the commercial strategy. The bear case is equally grounded in the persistent cash burn, high leverage, and a valuation that demands near-perfect execution. The single most important tension in the investment debate is the company's ability to translate its explosive top-line growth into sustainable positive cash flow before its capital runway is exhausted. The resolution of this cash burn timeline will determine if the stock can grow into its premium valuation or face a painful multiple compression.
Bullish
- Explosive Revenue Growth: Revenue grew 65% year-over-year to $196 million in Q4 2025, accelerating from prior quarters, demonstrating a successful commercial launch for its CNS therapies. This growth trajectory is critical for justifying its current valuation and path to profitability.
- High and Expanding Gross Margins: Gross margins are exceptionally strong at 93.7% in Q4 2025, typical of a successful pharmaceutical model, indicating pricing power and efficient manufacturing. This provides a robust foundation for future profitability as operating expenses are scaled.
- Strong Technical Momentum: The stock has gained 114.06% over the past year and 42.60% over the past three months, significantly outperforming the S&P 500's 27.04% gain. It is trading near its 52-week high of $238.56, reflecting strong positive momentum and investor confidence in the commercial story.
- Unanimous Analyst Buy Ratings: Covering firms, including Guggenheim and Wells Fargo, maintain 'Buy' or 'Overweight' ratings as of March 2026, signaling strong institutional conviction in the near-term commercial execution. This sentiment supports the stock's premium valuation despite the lack of profitability.
Bearish
- Persistent Losses and Cash Burn: The company remains deeply unprofitable with a net margin of -28.7% and generated negative free cash flow of -$93.8 million TTM. A negative ROE of -207.5% indicates the company is burning significant capital to fund growth, raising sustainability concerns.
- High Valuation Demands Perfection: With a trailing PS ratio of 14.2x, the stock is priced for flawless execution of massive future growth. The forward PS of 2.4x is based on estimated revenue of $3.76B, implying the market expects revenue to more than double, leaving no room for commercial missteps.
- Elevated Financial Leverage: A debt-to-equity ratio of 2.73 indicates significant leverage, which amplifies financial risk while the company is still cash flow negative. This necessitates future financing, which could be dilutive to shareholders if not executed from a position of strength.
- Limited Analyst Coverage & High Uncertainty: Only 8 analysts cover the stock, and revenue estimates for the forward period range widely from $3.16B to $4.48B, highlighting significant modeling uncertainty. This lack of consensus and coverage can lead to volatile price reactions to news.
AXSM Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 1-year price change of +114.06%, significantly outperforming the broader market's 27.04% gain. With a current price of $231.48, it is trading near the top of its 52-week range of $96.09 to $238.56, positioning it at approximately 95% of the range's high, indicating strong momentum but also potential vulnerability to a pullback from overbought conditions. The stock's beta of 0.598 suggests it has been less volatile than the market over the past year, which is atypical for a biotech but may reflect its transition to a commercial story. Recent momentum remains robust but shows signs of consolidation after a sharp run; the stock is up 3.77% over the past month and 42.60% over the past three months. The 1-month gain, while positive, is notably lower than the 3-month and 1-year returns, suggesting the explosive upside momentum may be moderating as the stock digests its massive gains. This deceleration is also reflected in a recent pullback from a late-May high near $236, with the price declining -2.01% on the last trading day. Key technical support is anchored at the 52-week low of $96.09, though more immediate support lies near the $160-$170 zone from the March consolidation. The primary resistance is the 52-week high of $238.56; a decisive breakout above this level could signal a continuation of the uptrend, while failure here may lead to a deeper correction. The stock's low beta of 0.598 implies it has exhibited only about 60% of the S&P 500's volatility, which is unusually low for a biotech and may indicate reduced speculative trading as the company matures.
Beta
0.60
0.60x market volatility
Max Drawdown
-18.5%
Largest decline past year
52-Week Range
$96-$258
Price range past year
Annual Return
+140.2%
Cumulative gain past year
| Period | AXSM Return | S&P 500 |
|---|---|---|
| 1m | +8.4% | -0.1% |
| 3m | +63.5% | +12.0% |
| 6m | +72.2% | +8.8% |
| 1y | +140.2% | +22.9% |
| ytd | +42.8% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXSM Fundamental Analysis
Axsome is demonstrating explosive revenue growth as it commercializes its CNS portfolio, with Q4 2025 revenue reaching $196.0 million, representing a year-over-year growth of 65.0%. This growth is accelerating from prior quarters, as Q3 2025 revenue was $171.0 million (up from $104.8 million in Q3 2024) and Q2 2025 was $150.0 million, indicating a strong commercial launch trajectory. The revenue segment data confirms that nearly all sales ($194.7 million in Q4) are derived from product revenue, underscoring the successful transition to a commercial entity. Despite soaring sales, the company remains unprofitable on a net income basis, reporting a Q4 net loss of $28.6 million. However, this represents a significant improvement from a net loss of $74.9 million in the year-ago quarter. Gross margins are exceptionally high at 92.5% (Q4 gross margin of 93.7%), typical for a pharmaceutical company, but operating losses persist with an operating margin of -26.5%, reflecting heavy investment in commercialization and R&D. The balance sheet shows a debt-to-equity ratio of 2.73, indicating significant leverage, though the current ratio of 1.55 suggests adequate short-term liquidity. A major concern is cash flow; the company generated negative free cash flow of $93.8 million (TTM) and negative operating cash flow of $18.7 million in the latest quarter. The negative ROE of -207.5% and ROA of -16.8% highlight that the company is burning capital to fund growth, making future financing a key monitorable for investors.
Quarterly Revenue
$195999000.0B
2025-12
Revenue YoY Growth
+0.65%
YoY Comparison
Gross Margin
+0.93%
Latest Quarter
Free Cash Flow
$-93814000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXSM Overvalued?
Given the company's negative net income and negative EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 14.2x, while the forward PS ratio (based on estimated revenue of $3.76 billion) is approximately 2.4x, implying the market expects massive revenue growth to continue and is pricing the stock on future sales potential. The wide gap between trailing and forward multiples reflects high embedded growth expectations. Comparable industry valuation data is not provided in the dataset, making a precise peer comparison impossible. However, a PS ratio of 14.2x for a commercial-stage biotech with 65% YoY growth is not uncommon, though it demands flawless execution to justify. The lack of profitability and negative cash flows typically command a discount, but the premium is likely tied to the blockbuster potential of its CNS franchise. Historically, the stock's own valuation has expanded dramatically with its commercial success. The current PS ratio of 14.2x is significantly higher than levels seen in early 2024 (e.g., 34.6x in Q4 2024, 44.2x in Q2 2024, and over 50x in early 2023 when revenue was minimal). This compression in the multiple despite soaring revenue indicates the market is valuing sales more rationally as they scale, but the stock remains priced for perfection near the upper end of its own historical sales multiple range given its current growth phase.
PE
-49.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -81x~-9x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-53.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Axsome faces significant financial risk from its persistent cash burn and high leverage. The company reported negative free cash flow of -$93.8 million (TTM) and negative operating cash flow of -$18.7 million in the latest quarter, burning capital to fund its commercial expansion. With a debt-to-equity ratio of 2.73, the balance sheet is levered, and the negative ROE of -207.5% indicates the business is destroying shareholder equity. The path to profitability is not yet secured, and any slowdown in the 65% revenue growth rate would quickly expose these financial vulnerabilities, potentially forcing dilutive equity financing.
Market & Competitive Risks: The primary market risk is valuation compression. The stock trades at a trailing PS ratio of 14.2x, a premium multiple that embeds expectations for revenue to scale to an estimated $3.76 billion. If quarterly revenue growth decelerates or fails to meet the high end of analyst estimates (up to $4.48B), the multiple could contract sharply. Furthermore, the stock's low beta of 0.598 is atypical for a biotech and may not be sustainable; a reversion to sector-typical volatility could increase downside risk. Competitive threats in the crowded CNS market could also pressure pricing and market share for its lead product, Auvelity.
Worst-Case Scenario: The worst-case scenario involves a combination of a significant commercial setback—such as a prescription slowdown for Auvelity—coinciding with a tightening capital market that limits financing options. This would force the company to raise capital on unfavorable terms, severely diluting shareholders, while the high debt burden becomes more onerous. In this adverse scenario, the stock could realistically re-test its 52-week low of $96.09, representing a downside of approximately -58% from the current price of $231.48. A more immediate bear-case target could be the $160-$170 support zone, implying a -30% to -31% decline.
FAQ
The key risks are, in order of severity: 1) Financial Sustainability: The company burns cash (-$93.8M TTM FCF) and carries high debt (D/E of 2.73), risking dilution or financial distress if growth slows. 2) Valuation Compression: The stock's 14.2x PS ratio demands flawless execution; any growth deceleration could trigger a severe multiple contraction. 3) Commercial Execution: Future revenue growth from $196M per quarter is not guaranteed in the competitive CNS market. 4) Limited Analyst Coverage: Only 8 analysts cover the stock, leading to less efficient price discovery and potentially higher volatility on news.
The 12-month forecast presents three scenarios with associated probabilities. The Base Case (50% probability) targets a range of $210-$240, assuming revenue grows in line with analyst averages (~$3.76B) and losses continue to narrow. The Bull Case (25% probability) targets $265-$285, requiring revenue growth to sustain above 60% and a path to profitability becoming visible. The Bear Case (25% probability) targets $96-$160, triggered by a growth slowdown and dilutive financing. The Base Case is most likely, centered on continued strong commercial execution but without the multiple expansion needed for the bull case. The key assumption is that quarterly revenue growth remains above 40%.
AXSM appears overvalued based on near-term fundamentals but could be fairly valued if its long-term growth targets are met. The trailing Price-to-Sales (PS) ratio of 14.2x is high, reflecting a premium for its 65% revenue growth. However, the forward PS ratio of approximately 2.4x (based on estimated revenue of $3.76B) suggests the market is pricing in massive future sales growth. The valuation implies the market expects revenue to more than double from current run-rates. Compared to its own history, the multiple has compressed from over 50x as revenue has scaled, but it remains at the upper end for a company still reporting net losses and negative cash flow.
AXSM is a high-risk, high-reward investment that may be a good buy for aggressive growth investors comfortable with biotech volatility, but it is not suitable for all portfolios. The stock has massive upside if it executes its growth plan, with analyst revenue estimates as high as $4.48B, but it carries significant downside risk, with a potential -58% drawdown to its 52-week low if execution falters. At its current price near all-time highs and a demanding 14.2x PS ratio, the risk/reward is balanced, making it more appropriate for a 'watch and wait' approach or a small, speculative position rather than a core holding.
AXSM is primarily a long-term investment for investors with a 3-5 year horizon who can withstand high volatility. The company's story is about scaling to profitability, which will take multiple quarters, if not years, to play out. While the stock has shown strong momentum (+114% in 1 year), its low beta of 0.598 is anomalous and may not persist; typical biotech volatility could return. The lack of a dividend and earnings visibility makes it unsuitable for short-term income or trading, except for very experienced traders who can navigate biotech catalysts. The minimum suggested holding period is 18-24 months to allow for several earnings cycles to validate the growth trajectory.